A federal appeals court has reinstated multiple lawsuits alleging a connection between acetaminophen exposure during pregnancy and autism spectrum disorder development in children. The decision allows plaintiffs to proceed with litigation against pharmaceutical manufacturers, reviving claims that were previously dismissed. This ruling represents a significant development in ongoing legal battles concerning over-the-counter pain medication safety and potential neurodevelopmental risks. The case highlights growing concerns about prenatal drug exposure and its long-term health implications for offspring.

Summary auto-generated by AI from the original publisher's content. Editorial standards.